Genzyme's Carticel Knee Treatment Drives 56% Revenue Jump In 1998
This article was originally published in The Gray Sheet
Executive Summary
U.S. sales of Genzyme Tissue Repair's Carticel, approved by FDA in August 1997 for treatment of knee cartilage damage, increased 64% in the fourth quarter of 1998 to $2.6 mil., the company notes in reporting preliminary results. Worldwide sales of the autologous cultured chondrocytes product were up 49% to $3.3 mil.